Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes

PURPOSE: Treatment protocols for invasive lobular breast cancer (ILC) have largely followed those for invasive ductal breast cancer. This study compares treatment outcomes of endocrine therapy versus combined chemo-endocrine therapy in hormone-receptor-positive (HR+), HER2-positive (HER2+) ILC tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaghi, Marita, Bilani, Nadeem, Dominguez, Barbara, Jabbal, Iktej Singh, Rivera, Carlos, Bou Zerdan, Maroun, Li, Hong, Saravia, Diana, Stone, Elizabeth, Nahleh, Zeina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157253/
https://www.ncbi.nlm.nih.gov/pubmed/35640346
http://dx.doi.org/10.1016/j.breast.2022.05.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157253/
https://www.ncbi.nlm.nih.gov/pubmed/35640346
http://dx.doi.org/10.1016/j.breast.2022.05.005

Ejemplares similares